Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. TGTX Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

TG Therapeutics (TGTX)

Market Price (9/18/2025): $32.04 | Market Cap: $4.7 Bil
Sector: Health Care | Industry: Biotechnology

TG Therapeutics (TGTX)

Market Price (9/18/2025): $32.04
Market Cap: $4.7 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31%		 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 48x, P/EPrice/Earnings or Price/(Net Income) is 78x
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 19%		  Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2%
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 19%
2 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17%
3 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 48x, P/EPrice/Earnings or Price/(Net Income) is 78x
4 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2%

Market Valuation

 9/18/252024202320222021
Share Price CYE$32.04$30.10$17.08$11.83$19.00
Market Cap CYE ($ Bil)4.74.42.41.62.5
Total Debt ($ Bil)0.30.30.10.10.1
Total Cash ($ Bil)0.30.30.20.20.3
Enterprise Value ($ Bil)4.74.72.51.72.6
Valuation Ratios     
P/S TTM10.313.310.4575.2375.6
P/EBIT TTM48.288.294.4-7.5-7.3
P/E TTM77.8187.1191.3-7.2-7.2
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$32.04$30.10$17.08
Market Cap CYE ($ Bil)4.74.42.4
Total Debt ($ Bil)0.30.30.1
Total Cash ($ Bil)0.30.30.2
Enterprise Value ($ Bil)4.74.72.5
Valuation Ratios   
P/S TTM10.313.310.4
P/EBIT TTM48.288.294.4
P/E TTM77.8187.1191.3
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
TGTX Return369%-63%-38%44%76%6%190%
Peers Return33%-0%18%14%-2%10%91%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: KURA, ABBV, AMGN, GILD, VRTX. See TGTX Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than TG Therapeutics (TGTX)

 TGTXBetter Performance than TGTX
MetricValueIndustry (Biotechnology)
Rev Chg LTM31.0%MDGL (3422.0%), HALO (35.0%), RYTM (53.5%), AXSM (69.8%), CYTK (2635.7%)
Rev Chg 3Y Avg539.4%BBIO (1225.0%), AXSM (699.5%), CYTK (824.6%), ARWR (908.8%), IBRX (1455.1%)
Op Mgn LTM18.9%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), REGN (27.0%), BIIB (23.2%)
CFO/Rev LTM-13.0%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-13.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield1.3%ABBV (3.9%), AMGN (7.8%), GILD (7.3%), VRTX (3.7%), REGN (7.5%)
 TGTXBetter Performance than TGTX
MetricValueAll Other Sectors
Rev Chg LTM31.0%NVDA (71.6%), PLTR (38.8%), APP (48.2%), MU (58.2%), APH (40.5%)
Rev Chg 3Y Avg539.4%QXO (1115.2%), PFLT (12481.5%), URG (7785.9%), GEVO (729.7%), HYLN (1262.5%)
Op Mgn LTM18.9%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM-13.0%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-13.0%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield1.3%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1TG Therapeutics Earnings Notes  
2TGTX's 28% Decline in a Month Brings Valuations Into Focus - Is STOK a Better Deal?Counter-Intuitive Comparisons 
3TGTX Dip Buy Analysis  
4TG Therapeutics Total Shareholder Return (TSR): 76.2% in 2024 and 16.6% 3-yr compounded annual returns (above peer average)  
5TG Therapeutics Market PriceMarket Price 
6TG Therapeutics (TGTX) Operating Cash Flow ComparisonFinancials 
7TG Therapeutics (TGTX) Net Income ComparisonFinancials 
8TG Therapeutics (TGTX) Operating Income ComparisonFinancials 
9TG Therapeutics (TGTX) Revenue ComparisonFinancials 
10TG Therapeutics (TGTX) worth $4.7 Bil (down $-1.2 Bil), still more valuable than Super Micro ComputerNotification 
11ARTICLES  
12Market Movers | Winners: COMM, SCS, IDXX | Losers: REPL, TGTX, ON August 5th, 2025
13Down 57% In A Month, Is There More Pain For TG Therapeutics Stock? January 28th, 2022
14Is A Rise Imminent For TG Therapeutics Stock After A Large 50% Fall In A Month? December 8th, 2021
15What’s Next For TG Therapeutics Stock After The Recent 25% Fall? May 20th, 2021
Title
0DASHBOARDS
1Market Movers | Winners: COMM, SCS, IDXX | Losers: REPL, TGTX, ON
2Down 57% In A Month, Is There More Pain For TG Therapeutics Stock?
3Is A Rise Imminent For TG Therapeutics Stock After A Large 50% Fall In A Month?
4What’s Next For TG Therapeutics Stock After The Recent 25% Fall?
5ARTICLES
6TG Therapeutics Earnings Notes
7TGTX's 28% Decline in a Month Brings Valuations Into Focus - Is STOK a Better Deal?
8TGTX Dip Buy Analysis
9TG Therapeutics Total Shareholder Return (TSR): 76.2% in 2024 and 16.6% 3-yr compounded annual returns (above peer average)
10TG Therapeutics Market Price
11TG Therapeutics (TGTX) Operating Cash Flow Comparison
12TG Therapeutics (TGTX) Net Income Comparison
13TG Therapeutics (TGTX) Operating Income Comparison
14TG Therapeutics (TGTX) Revenue Comparison
15TG Therapeutics (TGTX) worth $4.7 Bil (down $-1.2 Bil), still more valuable than Super Micro Computer

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for TG Therapeutics

Financials

TGTXKURAABBVAMGNGILDVRTXMedian
NameTG Thera.Kura Onc.AbbVie Amgen Gilead S.Vertex P. 
Mkt Price32.048.09220.81274.71112.26387.15166.53
Mkt Cap4.70.7390.4147.8139.899.4119.6
Rev LTM4548358,32834,91728,86211,41920,140
Op Inc LTM86-22013,6958,19210,797-1994,139
FCF LTM-5912318,23910,6059,3693,5006,434
FCF 3Y Avg-51-4720,2738,5908,3971,9845,191
CFO LTM-5912519,28312,0139,8683,8466,857
CFO 3Y Avg-51-4621,1549,7538,9492,3245,636

Growth & Margins

TGTXKURAABBVAMGNGILDVRTXMedian
NameTG Thera.Kura Onc.AbbVie Amgen Gilead S.Vertex P. 
Rev Chg LTM31.0%-6.1%12.9%3.8%10.5%10.5%
Rev Chg 3Y Avg539.4%-0.6%10.0%1.6%11.0%10.0%
Rev Chg Q92.1%-6.6%9.4%1.8%12.1%9.4%
QoQ Delta Rev Chg LTM17.5%22.5%1.7%2.3%0.4%2.9%2.6%
Op Mgn LTM18.9%-263.8%23.5%23.5%37.4%-1.7%21.2%
Op Mgn 3Y Avg-253.0%-27.2%26.4%39.2%26.5%26.5%
QoQ Delta Op Mgn LTM3.4%35.4%1.0%1.6%-0.0%2.0%1.8%
CFO/Rev LTM-13.0%150.1%33.1%34.4%34.2%33.7%33.9%
CFO/Rev 3Y Avg-219.9%-37.5%32.0%31.9%22.5%31.9%
FCF/Rev LTM-13.0%147.5%31.3%30.4%32.5%30.6%31.0%
FCF/Rev 3Y Avg-220.0%-36.0%28.2%30.0%19.2%28.2%

Valuation

TGTXKURAABBVAMGNGILDVRTXMedian
NameTG Thera.Kura Onc.AbbVie Amgen Gilead S.Vertex P. 
Mkt Cap4.70.7390.4147.8139.899.4119.6
P/S10.48.56.74.24.88.77.6
P/EBIT48.2-3.766.314.317.022.619.8
P/E77.8-3.6103.722.322.127.324.8
P/CFO-79.55.720.212.314.225.813.2
Total Yield1.3%-27.8%3.9%7.8%7.3%3.7%3.8%
Dividend Yield0.0%0.0%2.9%3.4%2.8%0.0%1.4%
FCF Yield 3Y Avg-1.0%0.3%7.3%6.2%8.0%2.1%4.1%
D/E0.10.00.20.40.20.00.1
Net D/E0.0-0.90.20.30.1-0.00.1

Returns

TGTXKURAABBVAMGNGILDVRTXMedian
NameTG Thera.Kura Onc.AbbVie Amgen Gilead S.Vertex P. 
1M Rtn15.5%8.2%6.9%-6.1%-4.2%-0.7%3.1%
3M Rtn-8.9%33.5%20.1%-4.4%4.7%-13.7%0.1%
6M Rtn-24.6%11.3%5.9%-11.5%5.9%-24.5%-2.8%
12M Rtn27.8%-59.9%18.2%-14.7%39.2%-19.6%1.8%
3Y Rtn371.9%-38.7%71.6%30.8%90.5%33.6%52.6%
1M Excs Rtn13.2%5.8%4.5%-8.5%-6.5%-3.0%0.8%
3M Excs Rtn-18.8%20.2%9.8%-14.8%-5.7%-22.7%-10.3%
6M Excs Rtn-37.2%-7.3%-12.4%-29.9%-14.3%-42.0%-22.1%
12M Excs Rtn17.7%-78.6%0.4%-31.9%22.3%-37.6%-15.7%
3Y Excs Rtn261.0%-106.6%13.2%-33.4%25.2%-28.7%-7.7%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/8/20255/9/20253/3/202511/7/20248/9/20245/6/20242/29/202411/6/20238/4/20235/8/20233/1/202311/9/2022
Key Financials Quarterly            
Total Revenue1411211088473634416616800
Ebitda3812331511-8-12118-44-36-75-34
Operating Income35930129-9-12115-45-37-78-35
Net Income2852347-11-14114-48-39-78-36
EPS0.190.030.160.030.05-0.07-0.100.80-0.34-0.28-0.39-0.26
Key Financials TTM            
Total Revenue TTM45438632926534728923419024935
Ebitda TTM98715061095426-38-190-183-213-230
Operating Income TTM866042-11024821-44-194-188-218-234
Net Income TTM603923-14964113-51-201-194-224-239
Growth Rates Quarterly            
Total Revenue Growth92.1%90.4%146.0%-49.4%357.0%713.5%54863.8%176298.9%2606.1%287.1%-96.6%-95.4%
EBITDA Growth255.6%247.8%383.2%-87.1%124.1%77.1%84.8%446.0%-17.5%45.2%18.1%59.7%
Operating Income Growth295.2%193.0%339.9%-89.2%119.7%74.9%83.9%428.3%-14.7%44.7%16.6%58.9%
Net Income Growth309.8%147.3%261.8%-96.6%114.4%72.7%81.6%418.1%-17.5%43.2%15.9%58.2%
Margins Quarterly            
EBITDA Margin26.7%10.2%30.1%18.1%14.4%-13.1%-26.2%71.0%-273.1%-464.8%-94353.8%-36213.8%
Operating Income Margin24.7%7.1%27.7%14.8%12.0%-14.6%-28.4%69.2%-277.9%-474.1%-96923.8%-37194.7%
Net Income Margin20.0%4.2%21.6%4.6%9.4%-16.9%-32.8%68.7%-296.2%-502.8%-98088.8%-38104.3%
Cash & Debt            
Total Cash252276311341217210218229145140162176
Total Debt2542542542541131121111101091088382
Net Debt / (Cash)2-23-57-87-105-98-107-119-36-32-79-94
Cash Flows Quarterly            
FCF from Operations7-29-26-126-8-1384-42-60-24-34
Cash Flows TTM            
FCF from Operations TTM-59-61-41-286820-31-42-160-167-176-239
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases7672-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC7.3%1.9%6.5%2.7%2.2%-2.3%-3.1%29.7%-11.0%-9.5%-20.6%-9.4%
Return on Invested Capital (ROIC) TTM            
ROIC TTM4.5%3.3%2.3%-0.0%6.2%3.0%1.2%-2.9%-12.0%-12.1%-14.5%-15.8%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
License, milestone, royalty and other revenue1420   
BRIUMVI920   
UKONIQ03   
License Revenue  0  
Other Revenue  0  
Product revenue, net  7  
Single Segment   00
Total2343700


Price Behavior

TGTX Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-1.85-0.76-0.180.420.671.76
Up Beta-5.39-3.88-2.140.170.181.96
Down Beta0.720.080.670.190.351.44
Up Capture-225%-43%-23%76%180%1515%
Bmk +ve Days10223571142415
Stock +ve Days11192963124368
Down Capture28%198%129%99%121%107%
Bmk -ve Days11192754106334
Stock -ve Days10223362123380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity24,510,079
Short Interest: % Change Since 81520254.1%
Average Daily Volume1,836,747
Days-to-Cover Short Interest13.34
Basic Shares Quantity146,739,833
Short % of Basic Shares16.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/4/2025-18.0%-23.7%-15.1%
3/3/202514.4%27.8%31.0%
11/4/2024-9.4%7.1%24.1%
8/6/202419.6%20.0%28.3%
2/28/202426.7%30.0%11.9%
11/1/202330.9%40.1%65.7%
8/1/2023-49.3%-51.2%-49.4%
2/28/20230.6%9.7%-8.0%
...
SUMMARY STATS   
# Positive101211
# Negative978
Median Positive17.0%14.9%14.8%
Median Negative-9.4%-23.7%-19.4%
Max Positive63.4%64.0%65.7%
Max Negative-49.3%-51.2%-52.5%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025808202510-Q 6/30/2025
3312025509202510-Q 3/31/2025
12312024303202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024809202410-Q 6/30/2024
3312024506202410-Q 3/31/2024
12312023229202410-K 12/31/2023
930202311062023null 9/30/2023
6302023804202310-Q 6/30/2023
3312023508202310-Q 3/31/2023
12312022301202310-K 12/31/2022
93020221109202210-Q 9/30/2022
6302022809202210-Q 6/30/2022
3312022510202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211108202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Power Sean ACFO1072025Sell30.2911,337343,44320,316,126Form
1Lonial Sagar 11122024Sell30.445,000152,2003,049,936Form
2Charney Laurence N 11122024Sell30.2025,000754,8756,415,803Form
3Echelard Yann 11072024Sell24.4820,000489,6005,485,919Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.